

2024 Annual Report



MISSION STATEMENT

Putting people with lupus at the center of all we do, the Lupus Research Alliance drives the discovery and development of next generation lupus diagnostics and curative treatments through innovative research and collaborations.

BECAUSE OF YOU, WE ARE MOVING CLOSER TO A CURE

This was a landmark year for the lupus community and the Lupus Research Alliance. Together, we're pushing the boundaries of scientific innovation and advancing pioneering research to realize our vision: a world free of lupus. Fueled by your support, we remain steadfast in our commitment to support the full continuum of lupus research – from groundbreaking discoveries in the lab to clinical breakthroughs. Every program we invest in is a catalyst, accelerating progress toward personalized treatments and a cure.

A YEAR OF ADVANCING LUPUS RESEARCH TOGETHER

In 2024, the Lupus Research Alliance invested nearly \$12.9 million in innovative lupus research, bringing our total investment since 1999 to more than \$284 million and supporting over 660 individual research awards. Each of these efforts is designed with one goal in mind: improving the lives of people with lupus by accelerating discoveries, advancing new therapies, and ultimately delivering a cure.

Looking back on 2024, we see a year defined by progress, not just in science, but in partnership with the lupus community. Your stories, strength, and voices shape our priorities and drive our mission forward. We are deeply grateful to the people in our community who share their time, insights, and experiences with us. Your involvement ensures that lupus research is informed and impactful.

The Lupus Research Alliance, together with clinical affiliate, Lupus Therapeutics, remains the only lupus research organization spanning the full continuum of discovery. Lupus Therapeutics, which oversees the Lupus Clinical Investigators Network (LuCIN), continues to forge powerful collaborations with biopharmaceutical partners, advancing promising therapies at every stage of development, including trials targeting potential next-generation treatments like T cell activators.

DIVING DEEPER INTO A YEAR OF IMPACT

From fueling breakthrough science to expanding powerful partnerships, the Lupus Research Alliance, alongside the lupus community, is driving real change and accelerating the path to a cure. In 2024, we made major strides that:

- **Fueled transformative science** including the Lupus Innovation Awards, Lupus Insight Prize, and the first-ever Translational Bridge Awards, Targeted Research Program on Engineered Cell Therapies for Lupus, and Empowering Lupus Research Career Development and Postdoctoral Awards. These programs fund bold ideas, nurture rising scientific talent, and advance discoveries that improve diagnostics, treatment, and the lives of people living with lupus around the globe.
- **Achieved groundbreaking clinical progress** with Lupus Therapeutics helping to advance multiple late-stage trials showing positive results for systemic lupus erythematosus and lupus nephritis treatments while also launching innovative funding for diet and microbiome-related studies – IDEAL (Investigate Dietary Approaches for Lupus). Currently, Lupus Therapeutics is involved in more than 25% of active lupus clinical trials, helping advance novel therapies through broad clinical expertise, strong research partnerships, and community engagement.
- **Celebrated the first anniversary of the Lupus Accelerating Breakthroughs Consortium (Lupus ABC)**, a unique public-private partnership founded and led by the Lupus Research Alliance. This powerful consortium brings together patients, scientists, industry, advocacy groups, and government agencies to fast-track solutions and deliver safer, more effective treatments. This year, the FDA's Center for Biologics Evaluation and Research joined the effort, enhancing its focus on engineered cell therapies.
- **Launched the DREAM**, a game-changing data and engagement platform (Data Repository, Exchange and Analytics platform), giving researchers access to vital data and offering people with lupus a new way to participate in studies, access support, and see how their data is shaping the future of lupus research. The DREAM is a key component of the Lupus Nexus, launched in 2023 as a unique resource to accelerate precision medicine in lupus.
- **Engaged thousands of lupus community members** at signature Lupus Research Alliance events like the New Jersey and New York "Walk with Us to Cure Lupus" events, and the star-studded 2024 Gala. These events not only brought our community together in solidarity; they raised nearly \$4.5 million to accelerate research and elevate lupus awareness.

FROM YOUR VOICE COMES PROGRESS

Our community is at the heart of everything we do. We are deeply grateful to every individual who has shared their story, participated in clinical research, walked beside us, raised awareness, and helped propel lupus research forward. Your voices, actions, and advocacy make progress possible – and bring us closer to a cure.

The Lupus Research Alliance came into my life at a critical time, offering resources, support, and hope for a healthy and happy life with lupus. My legacy gift is not only a thank you, but a way to help build on the important work they do supporting lupus research and the community of patient and caregivers."

Jennifer Dakin
Lupus Research Alliance
Board Member &
Legacy Donor



LUPUS RESEARCH ALLIANCE REMAINS ONE OF THE MOST TRUSTED HEALTH ORGANIZATIONS

The Lupus Research Alliance is proud of its status as one of the best charities worldwide. The Lupus Research Alliance earned four out of four stars by Charity Navigator, the Gold Seal of Transparency from Guidestar, recognition as a BBB Wise Giving Accredited Charity and a “Top Rated” status with an “A” ranking from nonprofit evaluator CharityWatch.

The following is an overview of the Lupus Research Alliance’s income and expenditures for the fiscal year ending December 31, 2024.

Revenue & Other Support:	
Contributions	\$ 11,172,604
Other Support	\$ 7,669,830
Total Revenue & Other Support:	\$18,842,434

Program Expenditures:	
Research	\$ 14,619,194
Scientific programs	\$ 14,814,000
Public policy	\$ 571,134
Total Program Expenditures:	\$30,004,328


Administration Expenditures:	\$ 3,274,283*
------------------------------	---------------

Fundraising Expenditures:	\$ 4,204,298*
---------------------------	---------------

End-of-Year Net Asset Balance:	\$55,712,575
--------------------------------	--------------

Because the Lupus Research Alliance Board of Directors funds our administrative and fundraising costs, 100% of your contribution to the Lupus Research Alliance goes directly to support lupus research programs.

*The Lupus Research Alliances’s Supporting Services are covered by donations from its Board of Directors.



Board of Directors

We extend our sincere gratitude and appreciation to our Board of Directors, who fund all our administration and fundraising expenses. Their ongoing generosity allows us to commit 100% of all other donations to support lupus research programs.

- Ira Akselrad, Chair
- Anna Fisch, Secretary
- Joseph Mauriello, Treasurer
- James Andrew
- Bishop Rudy V. Carlton
- Andrew C. Chan, MD, PhD
- William “Willie” Colon
- Jennifer Dakin
- Jennie L. DeScherer
- Katey Driscoll
- Joe Germanotta
- Xavier Goss
- David M. Kies
- Gary Koretzky, MD, PhD
- Veronica Vargas Lupo
- Nadeem Meghji
- William J. Mulvihill
- Nidhi Patel
- Robert Seder, MD
- Daniel J. Wallace, MD, FACP, MACR
- Julius Williams
- William J. Wolfe
- Spencer Zwick

Officers

- Albert T. Roy, President & CEO
- Stacie Bell, PhD, Chief Clinical Research Officer, Lupus Therapeutics, LLC
- Nicole Capossela, Chief Advancement Officer
- Debra Rose, Chief Financial Officer
- Teodora Staeva, PhD, Chief Scientific Officer
- Luke Easley, VP, HR and Administration
- Penny Mitchell, VP, Marketing and Communications
- Andrea J. O’Neill, VP, Development

Scientific Advisory Board

- Andrew C. Chan, MD, PhD, Chair
- Laurent Arnaud, MD, PhD
- Roberto Caricchio, MD
- Kate Fitzgerald, PhD
- Nancy Gonzalez
- Judith James, MD, PhD
- Andrea Knight, MD
- Jason Williams

